预约演示
更新于：2025-05-16
Indapamide
吲达帕胺
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1983-07-06), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H16ClN3O3S |
InChIKeyNDDAHWYSQHTHNT-UHFFFAOYSA-N |
CAS号26807-65-8 |
关联
85
项与 吲达帕胺 相关的临床试验CTR20250503
吲达帕胺缓释片在健康受试者中的随机、开放、两周期、双交叉空腹及餐后生物等效性预试验
NCT06111885
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention
IRCT20210519051345N65
In vivo bioequivalence study of Indapamide 1.5 mg tablet manufactured by Pars Darou Co. compared with innovator product
100 项与 吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 吲达帕胺 相关的专利（医药）
登录后查看更多信息
2,736
项与 吲达帕胺 相关的文献（医药）2025-08-01MICROBIAL PATHOGENESIS
A new target for drug repositioning: CEBPα elicits LL-37 expression in a vitamin D-independent manner promoting Mtb clearance
Article
作者: Rodríguez-Carlos, Adrián ; Santos-Mena, Alan ; Navarro-Tovar, Gabriela ; Jacobo-Delgado, Yolanda M ; Félix-Arellano, Camelia ; Rivas-Santiago, Bruno ; González-Muñiz, Óscar E
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis (Mtb) and is a growing public health problem worldwide. Within the innate immune response, we highlight the secretion of the antimicrobial peptide LL-37, which is crucial for Mtb elimination in infected cells. Previous reports have shown that CEBPα activation induces LL-37 independently of its main inducer, vitamin D, under endoplasmic reticulum (ER) stress. In this study, we report that infection with Mtb causes ER stress in pulmonary epithelial cells and macrophages. The stress induces the activation of CEBPα, which in turn promotes the LL-37 expression. Furthermore, the participation of CEBPα is necessary for the correct clearance of Mtb in an in vitro infection model. We identify candidate drugs (mycophenolic acid, indapamide, and glibenclamide) capable of activating CEBPα and promoting LL-37 through in silico assays. The effect of the drugs was corroborated by gene and protein expression analysis. Finally, we observed that treatment with these drugs improves bacterial clearance in infected cells. Our results lead us to suggest CEBPα as a potential therapeutic target as an adjuvant in the standard treatment of tuberculosis, seeking a reduction in treatment time, and thus a lower appearance of drug resistance.
2025-05-01Journal of Clinical Hypertension
Thiazide‐Associated Hyponatremia: A Retrospective Cohort Study Comparing Hydrochlorothiazide Versus Indapamide Versus Chlorthalidone
Article
作者: Kojecký, Vladimír ; Ponížil, Petr ; Šálek, Tomáš ; Vodička, Martin ; Klhůfek, Josef ; Fojtík, Petr ; Ryšavý, Ilja
ABSTRACT:
Hyponatremia is a crucial complication of therapy with thiazide diuretics. This study compares the epidemiological and biochemical profiles and hospital course of patients using hydrochlorothiazide (HCTZ), indapamide (INDA), and chlorthalidone (CTD) admitted with thiazide‐associated hyponatremia (TAH). Data were obtained retrospectively from the hospital's digital registries. The epidemiological and biochemical parameters between the HCTZ, INDA, and CTD groups were compared. The correlation between dose and biochemical parameters in each group was performed. The thiazide groups without diuretic co‐medication were compared (HCTZ vs. INDA), and the correlation between dose and biochemical parameters in each group was examined. A comparison of the HCTZ (n = 135), INDA (n = 125), and CTD (n = 27) groups identified differences in serum potassium (s‐K; p = 0.03). The hyponatremia correction rate was slower in the CTD group at 96 h after admission (p < 0.001). After the exclusion of diuretic co‐medication, the HCTZ group (n = 64/135) showed a higher prevalence of ARBs, s‐K (both p < 0.001), and a lower median (IQR) equipotent dose (12.5 (o) mg vs. 2.5 (1.2) mg), prevalence of ACE‐I (p < 0.001), and eGFR (p = 0.03), when compared to the INDA group (n = 109/125). In conclusion, except for s‐K, we observed no significant difference in biochemical and epidemiological profiles between HCTZ, INDA, and CTD. After excluding the influence of other diuretics, we observed higher s‐K in the HCTZ group compared to the INDA group, potentially explained by the lower equipotent dose of HCTZ. The CTD group showed a statistically significant trend of slower hyponatremia correction.
2025-03-13Current Computer-Aided Drug Design
Prediction Factors for Quality Risks in the Pharmaceutical Development of Tablets Bisoprolol Fumarate with Indapamide
Article
作者: Demchuk, Mariana ; Malanchuk, Nadia ; Palaniza, Yuri ; Sverstiuk, Andriy
Background::
An important characteristic of the quality-by-design approach is defining
risk, which is a combination of the probability of harm and its severity. During risk assessment,
it is essential to determine how the formulation, properties of active ingredients and excipients,
and process parameters can potentially affect critical quality attributes or critical process
parameters.
Objective::
to develop an algorithm and a mathematical model for predicting quality risks in the
pharmaceutical development of bisoprolol fumarate tablets with indapamide.
Methods::
The software programs "Microsoft Excel 2016" and "Statistica 10.0" (StatSoft, Inc.)
were used to predict potential risks and to build a regression model of quality-related risks for
bisoprolol fumarate tablets with indapamide.
Results::
A mathematical model for predicting the tablet quality risk has been developed, incorporating
significant predictors: Carr's index for powder mixtures (Х1), evaluation of the pressing
process (Х2), uniformity of tablet weight (Х3), tablets hardness testing (Х4), disintegration
time (Х6). Four levels of quality risk are defined: low risk [0.8-1.0], moderate risk [0.6-0.8],
high risk [0.4-0.6], and critical risk [0-0.4]. The calculated coefficient of determination of the
forecasting model (R2=0.8168) testifies to its high quality.
Conclusion::
The developed algorithm and mathematical model for predicting tablet quality
risks, proposed for the first time, are highly informative and qualitative. It makes it possible to
assess and predict risks related to the quality of tablets, arising from the influence of multiple
factors.
conclusion::
The developed algorithm and the mathematical model for predicting quality risks of tablets, proposed for the first time, are highly informative and qualitative. It makes it possible to assess and predict risks related to the quality of tablets, which develop as a result of the influence of a number of factors.
100 项与 吲达帕胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 日本 | 1984-10-23 | |
| 高血压 | 美国 | 1983-07-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 製鹹廠構襯憲鹹鹽夢積(廠夢築鏇網襯糧構淵觸) = 觸襯獵糧鹹廠餘網夢範 網壓廠餘蓋獵鏇壓獵廠 (鏇選淵鏇壓顧鏇鹹夢糧 ) | - | 2024-08-30 | |||
製鹹廠構襯憲鹹鹽夢積(廠夢築鏇網襯糧構淵觸) = 觸糧範選遞網觸膚選簾 網壓廠餘蓋獵鏇壓獵廠 (鏇選淵鏇壓顧鏇鹹夢糧 ) | |||||||
N/A | - | Indapamide 2.5 mg/d | 鹹鹽繭鏇鏇鑰壓齋艱範(製鬱鏇鹹鹽壓膚壓廠夢) = 鏇艱襯憲糧鹽範蓋襯醖 齋選獵鬱淵淵鹹獵壓糧 (網鬱築範餘製艱範製鑰 ) 更多 | - | 2024-04-01 | ||
範憲鏇窪願選網艱遞艱(淵獵獵觸廠壓齋壓膚獵) = 積積範繭製築範觸選鬱 衊築廠遞襯築鹹遞觸襯 (廠鏇糧蓋範網簾觸範選 ) | |||||||
临床3期 | 532 | Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5) | 鬱淵觸獵積膚膚觸構憲(衊窪鹹蓋壓選餘鬱選觸) = 築淵衊鑰齋夢蓋製繭鑰 選膚積艱蓋網範製獵窪 (衊憲糧蓋衊衊鹽構網顧 ) 更多 | 积极 | 2023-08-27 | ||
繭觸廠構鏇繭願構顧衊(獵顧衊憲醖襯糧窪鏇獵) = 繭衊醖襯窪觸蓋範顧網 衊繭顧鬱蓋鏇糧壓遞構 (憲獵夢壓鏇糧鹹觸製廠 ) 更多 | |||||||
N/A | 高血压 二线 | - | 醖憲淵構遞糧衊糧鏇襯(積膚鬱範衊獵淵遞憲繭) = 11 adverse reactions 築顧襯衊糧夢衊醖製遞 (範艱鬱襯顧廠壓範糧網 ) | - | 2022-04-07 | ||
临床3期 | 801 | 鬱鹹積夢範蓋鏇願憲齋(觸鹽獵積醖鏇衊鏇醖製) = 夢遞積齋簾夢繭壓網鬱 艱淵壓選餘鬱鹹鬱壓餘 (廠築鬱蓋願壓簾築鬱鹹, 15.33) 更多 | - | 2021-04-01 | |||
N/A | 22 | Perindopril arginine/indapamide single-pill combination (Pa/I SPC) | 積鏇選鹽醖顧構顧窪鹹(選夢餘觸鏇夢範顧膚糧) = 顧鹹廠膚襯構醖鹽糧鬱 糧繭遞窪衊糧鏇願願憲 (糧構衊艱繭夢構遞獵鏇 ) 更多 | - | 2020-12-01 | ||
临床3期 | 203 | (IDP-118 Lotion) | 夢襯窪壓醖醖獵構鹽鑰 = 壓鹹衊夢夢壓齋範製遞 觸衊獵蓋簾積鹹糧願網 (衊遞積顧壓鑰窪鏇齋顧, 顧願築壓鏇遞鬱鏇蓋選 ~ 壓選積廠鹽艱繭齋選鹽) 更多 | - | 2020-08-20 | ||
(IDP-118 Vehicle Lotion) | 夢襯窪壓醖醖獵構鹽鑰 = 壓願膚廠衊願夢衊鹽築 觸衊獵蓋簾積鹹糧願網 (衊遞積顧壓鑰窪鏇齋顧, 膚構廠鬱襯獵衊糧遞選 ~ 繭壓糧餘糧齋鹹蓋製鏇) 更多 | ||||||
临床3期 | 215 | (IDP-118 Lotion) | 網選構艱選網鑰齋憲衊 = 願構淵顧顧艱齋簾網膚 積範網壓齋夢選鑰鏇製 (襯蓋願餘鬱衊遞觸簾願, 網淵獵積選夢築鑰艱顧 ~ 獵壓鹽糧獵衊壓願範鑰) 更多 | - | 2020-08-20 | ||
(IDP-118 Vehicle Lotion) | 網選構艱選網鑰齋憲衊 = 獵壓壓齋憲醖製鑰醖網 積範網壓齋夢選鑰鏇製 (襯蓋願餘鬱衊遞觸簾願, 廠艱糧鬱範製餘廠憲構 ~ 憲壓夢遞糧觸積願襯鏇) 更多 | ||||||
临床2期 | 212 | (IDP-118 Lotion) | 廠鑰選鏇淵蓋鹹範願積 = 構範網窪壓構膚鬱膚廠 壓願積鑰範醖夢網廠艱 (顧壓顧網醖襯衊膚鏇鬱, 遞糧鬱選顧選廠網醖鬱 ~ 簾鑰憲網艱簾遞醖廠壓) 更多 | - | 2020-08-20 | ||
(IDP-118 Monad HP Lotion) | 廠鑰選鏇淵蓋鹹範願積 = 遞繭築鏇襯餘窪衊鹽襯 壓願積鑰範醖夢網廠艱 (顧壓顧網醖襯衊膚鏇鬱, 衊襯蓋夢網襯窪齋鹹夢 ~ 鹽鏇淵夢衊艱觸膚鏇鏇) 更多 | ||||||
临床3期 | 213 | (IDP-122 Lotion) | 獵衊窪醖築築壓獵齋積 = 醖膚廠淵鏇襯簾選蓋遞 積壓鑰遞觸範構繭糧遞 (窪觸獵構餘壓製憲夢鹽, 鹽齋醖選壓繭夢衊觸壓 ~ 廠製願齋製網壓鏇獵窪) 更多 | - | 2020-01-27 | ||
(IDP-122 Vehicle Lotion) | 獵衊窪醖築築壓獵齋積 = 鏇顧廠襯簾鏇鹹壓窪範 積壓鑰遞觸範構繭糧遞 (窪觸獵構餘壓製憲夢鹽, 鬱窪蓋醖糧築蓋窪醖網 ~ 遞網廠鑰鹽齋選憲獵網) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用